Erratum: Liver fibrosis staging with contrast-enhanced ultrasonography: Prospective multicenter study compared with METAVIR scoring (European Radiology (2009) 10.1007/s00330-009-1313-x);Liver fibrosis staging with contrast-enhanced ultrasonography: Prospective multicenter study compared with METAVIR scoring

European Radiology

Volumn 19, Issue 8, 2009, Pages 1991-1997

  Staub, F ^a,e   Tournoux Facon, C ^a   Roumy, J ^a   Chaigneau, C ^a   Morichaut Beauchant, M ^a   Levillain, P ^a   Prevost, C ^a   Aube C ^b   Lebigot, J ^b   Oberti, F ^b   Galtier, J B ^d   Laumonier, H ^d   Trillaud, H ^d   Bernard, P H ^d   Blanc, J F ^d   Sironneau, S ^d   Machet, F ^d   Drouillard, J ^d   de Ledinghen, V ^d   Couzigou, P ^d   Foucher, P ^d   Castera L ^d   Tranquard, F ^c   Bacq, Y ^c   d'Alteroche L ^c   Ingrand, P ^a   Tasu, J P ^a   more..

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e Fabrice Staub service de Radiologie   (France)

Author keywords

Contrast enhanced sonography; Fibrosis; Liver; Transit time

Indexed keywords

SONOVUE;

ADULT; AREA UNDER THE CURVE; ARM EDEMA; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE; DISEASE SEVERITY; ECHOGRAPHY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; ROC CURVE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STAGING;

EID: 67650917705     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1468-5     Document Type: Erratum

References (24)

1. Friedman SL (2004) Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1:98-105
2. Blanc JF, Bioulac-Sage P, Balabaud C et al (2005) Investigation of liver fibrosis in clinical practice. Hepatol Res 32:1-8
3. Blomley MJ, Lim AK, Harvey CJ et al (2003) Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: A cross sectional study. Gut 52:1188-1193
4. Lim AK, Taylor-Robinson SD, Patel N et al (2005) Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 54:128-133
5. Hashimoto K, Murakami T, Dono K et al (2006) Assessment of the severity of liver disease and fibrotic change: The usefulness of hepatic CT perfusion imaging. Oncol Rep 16:677-683
6. Ridolfi F, Abbattista T, Marini F et al (2007) Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 39:929-935
7. Kim H, Booth CJ, Pinus AB et al (2008) Induced hepatic fibrosis in rats: hepatic steatosis, macromolecule content, perfusion parameters, and their correlations - preliminary MR imaging in rats. Radiology 247:696-705
8. Albrecht T, Blomley MJ, Cosgrove DO et al (1999) Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 353:1579-1583
9. Pedersen JF, Larsen VA, Bytzer P et al (2005) Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 46:557-560
10. Searle J, Mendelson R, Zelesco M et al (2008) Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study. J Med Imaging Radiat Oncol 52:130-133
11. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417-422
12. Jalan R, Hayes PC (2000) UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 46(Suppl 3-4):III1-III15
13. Palma DT, Fallon MB (2006) The hepatopulmonary syndrome. J Hepatol 45:617-625
14. Mori H, Hayashi K, Fukuda T, Matsunaga N et al (1987) Intrahepatic portosystemic venous shunt: Occurrence in patients with and without liver cirrhosis. AJR Am J Roentgenol 149(4):711-714
15. Sherman IA, Papas SC, Fisher MM (1990) Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis. Am J Physiol 258:460-465
16. Sugimoto H, Kaneko T, Hirota M et al (2002) Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 37(5):578-583
17. Ohnishi K, Chin N, Saito M et al (1986) Portographic opacification of hepatic veins and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis - indication of extensive intrahepatic shunts. Am J Gastroenterol 81(10):975-978
18. Blomley MJ, Albrecht T, Cosgrove DO et al (1999) Stimulated acoustic emission to image a late liver and spleen-specific phase of Levovist in normal volunteers and patients with and without liver disease. Ultrasound Med Biol 25(9):1341-1352
19. Lim AK, Patel N, Eckersley RJ et al (2006) Hepatic vein transit time of SonoVue: A comparative study with Levovist. Radiology 240(1):130-135
20. Lim AK, Patel N, Eckersley RJ et al (2004) Evidence for spleen-specific uptake of a microbubble contrast agent: A quantitative study in healthy volunteers. Radiology 231:785-788
21. Friedrich-Rust M, Ong MF, Martens S et al (2008) Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gastroenterology 134:960-974
22. Poynard T, Morra R, Halfon P et al (2007) Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7:40
23. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449-1457
24. Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171